APA (7th ed.) Citation

Bohannon, M., Liu, M., Nadeau, P., Talton, J., Gibson, D., Datta, S., . . . De Benedetto, A. (2020). Topical doxycycline monohydrate hydrogel 1% targeting proteases/PAR2 pathway is a novel therapeutic for atopic dermatitis. Experimental dermatology, 29(12), 1171-1175. https://doi.org/10.1111/exd.14201

Chicago Style (17th ed.) Citation

Bohannon, Mary, Mingjin Liu, Peter Nadeau, Judy Talton, Daniel Gibson, Susmita Datta, Gregory Schultz, James Talton, and Anna De Benedetto. "Topical Doxycycline Monohydrate Hydrogel 1% Targeting Proteases/PAR2 Pathway Is a Novel Therapeutic for Atopic Dermatitis." Experimental Dermatology 29, no. 12 (2020): 1171-1175. https://doi.org/10.1111/exd.14201.

MLA (9th ed.) Citation

Bohannon, Mary, et al. "Topical Doxycycline Monohydrate Hydrogel 1% Targeting Proteases/PAR2 Pathway Is a Novel Therapeutic for Atopic Dermatitis." Experimental Dermatology, vol. 29, no. 12, 2020, pp. 1171-1175, https://doi.org/10.1111/exd.14201.